Company Description
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States.
The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer.
The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors.
It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab.
The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025.
NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Xi-Yong Fu |
Contact Details
Address: 2440 Research Boulevard, Suite 400 Rockville, Maryland 20850 United States | |
| Phone | 240 745 6330 |
| Website | novabridge.com |
Stock Details
| Ticker Symbol | NBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001778016 |
| CUSIP Number | 44975P103 |
| ISIN Number | US44975P1030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Xi-Yong Fu M.B.A., Ph.D. | Chief Executive Officer and Director |
| Ming Lei | Chief Financial Officer |
| Sean Wuxiong Cao M.B.A., Ph.D. | Chief Business Development Officer and Director |
| Mark Hagler | President and Chief Commercial Officer |
| Tyler Ehler | Senior Director of Investor Relations |
| Liwei Lin | General Counsel and Board Secretary |
| Dr. Cong Xu M.D., Ph.D. | Senior Vice President and Head of Research & Development Center of Excellence |
| Dr. Phillip Dennis M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2026 | 20-F/A | Filing |
| Jun 16, 2026 | 6-K | Report of foreign issuer |
| Jun 16, 2026 | 6-K | Report of foreign issuer |
| May 14, 2026 | 144 | Filing |
| Apr 22, 2026 | 6-K | Report of foreign issuer |
| Apr 7, 2026 | 6-K | Report of foreign issuer |
| Apr 7, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 18, 2026 | 144 | Filing |
| Mar 16, 2026 | 6-K | Report of foreign issuer |
| Mar 9, 2026 | 6-K | Report of foreign issuer |